Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (261-270 of 289) with videos related to

Pageof 29
Sort By:
Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.
Cancers|May 14, 2025
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil ModelHui Li, Morteza Salehjahromi, Myrna C B Godoy, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
The Journal of Clinical Investigation|April 4, 2018
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancerKe Gong, Gao Guo, David E Gerber, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Cancer Cell|October 20, 2023
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancerAnanda M Rodilla, Rajesh M Valanparambil, Philip C Mack, et al.
Journal for Immunotherapy of Cancer|September 10, 2025
Innate and adaptive immune features associated with immune-related adverse eventsShaheen Khan, Venkat S Malladi, Mitchell S von Itzstein, et al.
Vaccines|July 27, 2024
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung CancerPhilip C Mack, Chih-Yuan Hsu, Ananda M Rodilla, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Daniel Morgensztern, Meghan J Campo, Suzanne E Dahlberg, et al.
Pageof 29

Showing results (261-270 of 289) with videos related to

Sort By:
Pageof 29
Cancers|March 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor TherapyMitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield, et al.
Cancers|May 14, 2025
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil ModelHui Li, Morteza Salehjahromi, Myrna C B Godoy, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
The Journal of Clinical Investigation|April 4, 2018
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancerKe Gong, Gao Guo, David E Gerber, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Cancer Cell|October 20, 2023
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancerAnanda M Rodilla, Rajesh M Valanparambil, Philip C Mack, et al.
Journal for Immunotherapy of Cancer|September 10, 2025
Innate and adaptive immune features associated with immune-related adverse eventsShaheen Khan, Venkat S Malladi, Mitchell S von Itzstein, et al.
Vaccines|July 27, 2024
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung CancerPhilip C Mack, Chih-Yuan Hsu, Ananda M Rodilla, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Daniel Morgensztern, Meghan J Campo, Suzanne E Dahlberg, et al.
Pageof 29